Core Viewpoint - Huazhan Biotechnology (Qingdao) Co., Ltd. officially listed on the Hong Kong Stock Exchange, marking it as the 86th listed company in Qingdao and the second new listing of the year, following Taikaiying [1] Group 1: Company Overview - Huazhan Biotechnology, established in 2012 and headquartered in Qingdao, focuses on the research and development of protein drugs, particularly in the field of platelet-derived growth factor (PDGF) [2] - The company's core product, Pro-101-1, is the fastest PDGF candidate drug in clinical development for burn treatment in China, having completed Phase IIb clinical trials and expected to launch in China by 2027 [2] Group 2: Financial and Market Information - The offering price for Huazhan Biotechnology was set at HKD 38.20 per share, with a total global offering of 17.6488 million H shares, raising approximately HKD 670 million, and a net amount of about HKD 600 million after expenses [1] - On the first day of trading, the company's stock price faced pressure, closing at HKD 35.00 per share, a decline of 8.38% [1] Group 3: Use of Proceeds - The raised funds will primarily be used for clinical development and commercialization of core products, with approximately 61.8% allocated to Pro-101-1 and Pro-101-2, 18.8% for purchasing R&D and quality control equipment, and the remainder for other PDGF product development and operational funds [1] Group 4: Strategic Support and Impact - The company has received strong support from local government, with Qingdao Laoshang Technology Innovation Development Group holding a 9.09% stake as a significant strategic investor [2] - The listing is expected to accelerate the commercialization of core products, enhance brand influence, and attract capital and talent to the biopharmaceutical industry in Qingdao and Shandong, promoting regional industrial cluster development [2]

Core Viewpoint - The article discusses the role of Fibroblast Growth Factor 21 (FGF21) in the context of heart failure with preserved ejection fraction (HFpEF), highlighting its mechanism of action through inter-organ communication and its potential as a therapeutic target in cardiovascular metabolic diseases [4][5]. Group 1: FGF21's Inter-Organ Communication Effects - FGF21 plays a crucial role in regulating mitochondrial energy metabolism through the adipose-heart axis, which is essential for improving HFpEF [4]. - The protective effects of FGF21 on the heart are dependent on the adiponectin (APN) signaling pathway [5]. Group 2: Biological Functions of FGFs and Drug Development - The article emphasizes the diverse biological functions of FGFs, particularly FGF21, in maintaining metabolic homeostasis, including blood glucose and blood pressure regulation, and its implications for drug development targeting cardiovascular metabolic diseases [5][15]. Group 3: Insights into Protein Drug Development - The discussion includes the clinical translation challenges in the development of protein drugs based on FGF signaling pathways, indicating a need for innovative approaches in this area [5][15]. Group 4: Event Announcement - An upcoming lecture featuring researcher Lin Zhuofeng will delve into the inter-organ communication mechanisms of FGF21 and its implications for cardiovascular metabolic diseases, along with insights into drug development prospects [5][12].